Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.

Apellis Pharmaceuticals Inc.

In a report released today, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Apellis Pharmaceuticals, with a price target of $45.00. Ac...

H.C. Wainwright Sticks to Its Buy Rating for Apellis Pharmaceuticals (APLS)

TD Cowen analyst Phil Nadeau maintained a Buy rating on Apellis Pharmaceuticals today and set a price target of $45.00. The company’s shares closed...

TD Cowen Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)

In a report released yesterday, Lisa Walter from RBC Capital maintained a Hold rating on Apellis Pharmaceuticals, with a price target of $22.00. Th...

Apellis Pharmaceuticals (APLS) Receives a Hold from RBC Capital

Morgan Stanley analyst Judah Frommer maintained a Hold rating on Apellis Pharmaceuticals yesterday and set a price target of $25.00. The company’s ...

Market Cap	$2.50B	P/E Ratio	78.44
52W High	$35.72	52W Low	$16.10
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	43.4%	52W Position	17.9%
Overall Score	32	Value Score	40
Quality Score	--	Technical Score	25

EPS Current Est	$0.25	EPS Next Est	$-1.21
EPS Growth Est	-584.0%	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	APLS	$19.61	+0.36%	1.45M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	APLS	$19.61	+0.4%	1.45M
3
4
5
6

APLS

APLS

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Apellis Pharmaceuticals Inc. Data in Excel

Get Apellis Pharmaceuticals Inc. Data in Excel